Investors

At a Glance

Lexaria Bioscience Corp. (CSE:LXX; OTCQX:LXRP) is a research-driven company that has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes faster delivery of drugs into the bloodstream, healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules.

Lexaria’s DehydraTECH technology is covered by issued and pending patents in over 40 countries around the world. Lexaria’s first patent was issued by USPTO in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. Lexaria has filed for patent protection for delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors, tobacco and more.

Investor Contact

 

Alex Blanchard

Manager Corporate Communications and Investor Relations

778-796-1897

[email protected]

 

Investor FAQs 

 

What is Lexaria’s ticker symbol and where do the shares trade?

Lexaria Bioscience trades on the Canadian Securities exchange under the symbol LXX and on the OTCQX under the symbol LXRP.

 

What is Lexaria’s CUSIP number?

Lexaria’sCUSIP number is 52886N.

 

When is Lexaria’s fiscal year end?

Lexaria’s fiscal year end is August 31.

 

When is the next annual general meeting?

The next annual general meeting will be announced when available.

 

Who are Lexaria’s external auditors?

MNP LLP act as Lexaria’s external auditors.

 

Who is Lexaria’s Transfer Agent?

Lexaria’s transfer agent is Computershare Investor Services Inc.

Web: www.computershare.com

Phone: (800) 564-6253

Share Structure

As at:2018-10-31
Shares issued and outstanding 77,090,621
Options Granted 4,470,000
Warrants outstanding 3,981,599
Fully diluted85,542,220
Insider ownership – fully diluted 18,925,302

Analyst Coverage

Anthony de Ruijter
Fundamental Research Corp.

Auditors:
Davidson & Company LLP
1200 – 609 Granville St
PO Box 10372, Pacific Centre
Vancouver BC
Canada V7Y1G6

Corporate Lawyers:
Borden Ladner Gervais LLP
Bay Adelaide Centre, East Tower
22 Adelaide Street West
Toronto, ON, Canada
M5H 4E3
Andrew Powers
www.blg.com

Intellectual Property Lawyers:
Fisher Broyles
6000 Fairview Road
Suite 1200
Charlotte, NC  28210
U.S.A.
www.fisherbroyles.com

Trademark Lawyers:
Fisher Broyles
6000 Fairview Road
Suite 1200
Charlotte, NC  28210
U.S.A.
www.fisherbroyles.com